Graham Mills

Graham Mills, PhD, is a seasoned professional in the life sciences investment sector, currently serving as a Principal at Abingworth since January 2022. With extensive experience, Graham has held various roles including Investment Manager at AdvanCell and Board Observer positions for Iambic Therapeutics, Addition Therapeutics, and JustMilk. Prior engagement includes co-founding and managing techspert.io, and consulting roles for Abingworth and Johnson & Johnson. Graham's academic credentials include a PhD in Translational Cancer Research from the University of Cambridge and an MBA from the Quantic School of Business and Technology, alongside earlier studies in Genetics at Trinity College Dublin and Translational Cancer Medicine at King's College London.